https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25895 0.05). Chronic treatment of combination of genistein (10 mg/kg) and amitriptyline (5 mg/kg and 10 mg/kg) significantly reduced the immobility time as compared to control group (p<0.001) and was comparable to amitriptyline alone (10 mg/kg). However, no changes in anti-immobility activity in combination of subeffective doses of genistein (5 mg/kg) and amitriptyline (5 mg/kg) were observed. Genistein at its standard dose (10 mg/kg) rendered synergistic effects in combination with subeffective dose of amitriptyline (5 mg/kg) and additive effects in combination with therapeutic dose of amitriptyline (10 mg/kg).]]> Wed 11 Apr 2018 17:08:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9218 65 years of age) drivers (pooled OR 1.13; 95% CI 0.97, 1.31) than in drivers <65 years of age (pooled OR 2.21; 95% CI 1.31, 3.73), a result consistent with age-stratified risk differences reported in cohort studies. Anxiolytics, taken in single or multiple doses during the daytime, impaired driving performance independent of their half-lives. With hypnotics, converging evidence from experimental and epidemiological studies indicates that diazepam, flurazepam, flunitrazepam, nitrazepam and the short half-life non-benzodiazepine hypnotic zopiclone significantly impair driving, at least during the first 2–4 weeks of treatment. The accident risk was higher in the elderly (>65 years of age) who use tricyclic antidepressants (TCAs); however, the evidence for an association of antidepressants with accident risk in younger drivers was equivocal. Sedative but not non-sedative antidepressants were found to cause short-term impairment of several measures of driving performance. Limited epidemiological research reported that opioids may be associated with increased accident risk in the first few weeks of treatment. Conclusions: Benzodiazepine use was associated with a significant increase in the risk of traffic accidents and responsibility of drivers for accidents. The association was more pronounced in the younger drivers. The accident risk was markedly increased by co-ingestion of alcohol. Driving impairment was generally related to plasma half-lives of hypnotics, but with notable exceptions. Anxiolytics, with daytime dosing, impaired driving independent of their half-lives. TCAs appeared to be associated with increased accident risk, at least in the elderly, and caused short-term impairment in driving performance. Opioid users may be at a higher risk of traffic accidents; however, experimental evidence is limited on their effects on driving.]]> Wed 11 Apr 2018 14:30:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28741 Wed 11 Apr 2018 13:37:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:11302 Wed 11 Apr 2018 12:24:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25796 Tue 11 Feb 2020 09:19:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:666 Thu 25 Jul 2013 09:10:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:242 Thu 25 Jul 2013 09:09:27 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36111 Thu 06 Feb 2020 14:25:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36109 post hoc appraisal of the data was performed categorizing patients according to the Rome III subgrouping (PDS and EPS). Results: In total, 292 subjects were randomized; mean age=44 yrs. 21% had delayed gastric emptying. Neither antidepressant altered gastric emptying, even in those with baseline delayed gastric emptying. GA increased with ADTx (P=0.02). Neither antidepressant affected the maximal-tolerated volume (MTV) of the nutrient drink test although aggregate symptom scores improved compared to placebo (P=0.04). Patients with the combined EPS-PDS subtype (48%) had a lower MTV on the nutrient drink test compared to the EPS group at baseline (P=0.02). Postprandial bloating improved with both AMI (P=0.03) and ESC (P=0.02). Conclusions: Amitriptyline (50 mg) improves FD symptoms but does not delay gastric emptying, even in patients with baseline delayed gastric emptying. GA improved with low-dose ADTx; the precise mechanism of action is unknown warranting further study.]]> Thu 06 Feb 2020 14:11:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46832 Thu 01 Dec 2022 11:59:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19925 Sat 24 Mar 2018 08:03:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19975 Sat 24 Mar 2018 07:54:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5189 Sat 24 Mar 2018 07:47:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:190 Sat 24 Mar 2018 07:42:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28742 Sat 24 Mar 2018 07:37:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24125 Sat 24 Mar 2018 07:11:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34107 T CC genotype has been previously linked to FD and TT genotype to antidepressant response in depression. The ss genotype of the 5-HTT LPR variant of the serotonin transporter gene (SLC6A4) has been linked to selective serotonin reuptake inhibitor (SSRI) response. We aimed to examine whether GNβ3 825C>T and 5-HTT LPR polymorphisms result in differential treatment effects in FD patients receiving antidepressant therapy. Methods: Participants were randomized to receive placebo, 50 mg AMI, or 10 mg escitalopram (ESC). The primary end point was adequate relief for ≥5 weeks of the last 10 weeks. Genotyping of GNβ3 825C>T and 5-HTT LPR was performed utilizing PCR-based methods. Results: GNβ3 825C>T and 5-HTT LPR genotype data were available for 256 (88%) and 246 (84%) patients, respectively. Both polymorphisms were in Hardy-Weinberg equilibrium. In tests for differential treatment, neither 5-HTT LPR nor GNβ3 825C>T genotype influenced response to therapy (P=0.89 and P=0.54, respectively). Although there was a tendency for a more favorable response to ESC in the SS/LS genotype compared to the LL genotype groups (40% vs. 31% reporting adequate relief of FD symptoms) among those in the ESC treatment arm, this was not significant (P=0.43). Conclusions: GNβ3 825C>T and 5-HTT LPR genetic variants do not alter treatment response to tricyclic and SSRI antidepressants in FD.]]> Fri 08 Feb 2019 10:43:58 AEDT ]]>